Emerging studies suggest Retatru tide , a dual activator targeting both incretin and glucose-dependent insulinotropic polypeptide , could provide a significant step forward for weight loss . Early patient investigations have demonstrated substantial losses in abdominal tissue, potentially exceeding current obesity therapies . Despite this, further